Document Type

Conference Proceeding

Publication Date

9-10-2026

Abstract

Targeted and untargeted NMR metabolomics, particularly by utilizing our previously invented high-resolution magic angle spinning (HRMAS) technique, can measure pathological tissues prior to their pathological evaluations, biological fluids (serum, CSF, etc.) in 10uL scales, and live cellsin the amount of < 100,000. Furthermore, NMR metabolomics results can be quantitatively correlated with other omics’ results measured from other platforms.

In this presentation, we will illustrate the super utilities of NMR metabolomicsin medicine, with a primary focus on discussions of our NMRmetabolomics-AI-guided trans-omics evaluations of Human Acute Respiratory Distress Syndrome (ARDS), a severe, life-threatening clinical condition and representing ~10% of all ICU patients in the US, but with its molecular and metabolic mechanisms remain incompletely understood.

To address this gap, we used HRMAS NMR to investigate serum metabolomic profiles of ICU patients with and without ARDS. These metabolomic data were integrated with detailed clinical outcomes and serum proteomics measured using the Olink Proteomics platform.

Olink technology combines proximity extension assay (PEA) with next-generation sequencing (NGS), enabling sensitive and high-throughput protein quantification and providing insight into biological processes underlying disease progression.

NMR analysis of pre–COVID-19 serum samples, 74 ARDS patients (64 with matched Olink proteomics data) and 100 non-ARDS ICU controls, identified 37 spectral-region-of-interest (ROI) and various ROIs can differentiate ARDS from non-ARDS, and correlate with ARDS clinical criteria of the 28-day patient outcome. Olink analyses identified 88 FDR significant proteins. Quantitative analyses between NMR ROIs and Olink proteins identified correlations between150 proteins and 14 ROIs, with identifications of 104 potential metabolites.

Proteomics-metabolomics pathway connections between 150-proteins and 104-metabolites were investigated using Claude AI, that identified 8 potential pathways involving 21 unique proteins and 14 possible metabolites, that can improve protein ROC AUC from 0.89 to 0.92, and NMR AUC from 0.70 to 0.78 for differentiating patient 28-day outcomes.

Comments

8th Annual Metabolomics Association of North America (MANA) Conference, September 8-11, 2026, UC Davis, CA.

Download

Share

COinS